Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Translationally Relevant Oral Ruxolitinib Dosing Reduces Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis

Eduardo Huarte, PhD, Michael Peel, PhD, Katherine Verbist, PhD, Brittany Fay, Sabrin Albeituni, PhD, Kim E. Nichols, MD, Paul Smith, PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-139539

Published: 2020

Journal Articles

Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment

Eduardo Huarte, PhD, Michael Peel, PhD, Philip Dube, PhD, Lynn Stephens, Becky Stewart, Brian Long, Philip Czerniak, Julian Oliver, PhD, Paul Smith, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139805

Published: 2020

Journal Articles

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Eduardo Huarte, PhD, Roddy S O'Connor, PhD, Melissa Parker, Taisheng Huang, Michael C. Milone, Paul Smith

Blood (2019) 134 (Supplement_1): 1934.

https://doi.org/10.1182/blood-2019-128288

Published: 2019

Journal Articles

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Eduardo Huarte, PhD, Melissa Parker, Ashish Juvekar, Julian Oliver, Wenqing Yao, Paul Smith

Blood (2019) 134 (Supplement_1): 5608.

https://doi.org/10.1182/blood-2019-126749

Published: 2019

Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 739.

https://doi.org/10.1182/blood-2019-123374

Published: 2019

Journal Articles

Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD

Ashish Juvekar, Bruce Ruggeri, Sindy Condon, Andrew Borkowski, Reid Huber, PhD, Paul Smith

Blood (2018) 132 (Supplement 1): 4522.

https://doi.org/10.1182/blood-2018-99-112144

Published: 2018

Journal Articles

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

Ashish Juvekar, Bruce Ruggeri, Sindy Condon, Andrew Borkowski, Reid Huber, PhD, Paul Smith

Blood (2018) 132 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2018-99-112223

Published: 2018

Journal Articles

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Eliza Hawkes, Anthony Lawrie, Andrew Jack, Paul Smith, Christopher Pocock, MD PhD, Kirit M. Ardeshna, MB BChir, John Radford, MD FRCP, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, MD, David C. Linch

Blood (2018) 132 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2018-99-111824

Published: 2018

Journal Articles

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Blood (2018) 132 (20): 2154–2165.

https://doi.org/10.1182/blood-2018-05-849893

Published: 2018

Includes: Supplemental data

Journal Articles

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Blood (2017) 130 (Supplement 1): 267.

https://doi.org/10.1182/blood.V130.Suppl_1.267.267

Published: 2017

Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Blood (2017) 130 (Supplement 1): 1864.

https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864

Published: 2017

Journal Articles

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Blood (2016) 128 (22): 1746.

https://doi.org/10.1182/blood.V128.22.1746.1746

Published: 2016

Journal Articles

Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial

Andrea Kühnl, MD, Ridwan Shaikh, David Cunningham, Sharon L Barrans, Cathy H Burton, Andrew Jack, Mary Gleeson, Nicholas Counsell, Paul Smith, Oliver Schofield, David C. Linch, FRCP, Michael Hubank, PhD

Blood (2016) 128 (22): 1747.

https://doi.org/10.1182/blood.V128.22.1747.1747

Published: 2016

Journal Articles

RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy

Blood (2016) 128 (22): 3267.

https://doi.org/10.1182/blood.V128.22.3267.3267

Published: 2016

Journal Articles

R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of WaldenstrőM's Macroglobulinemia: A Randomised Phase II Study

Rebecca L Auer, MD PhD, Roger G Owen, Shirley D'Sa, Guy Pratt, MD FRCP FRCPath, Bilyana Popova, Laura Clifton Hadley, Oliver Schofield, Nicholas Counsell, Paul Smith

Blood (2016) 128 (22): 618.

https://doi.org/10.1182/blood.V128.22.618.618

Published: 2016

Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong

Blood (2016) 128 (22): 4508.

https://doi.org/10.1182/blood.V128.22.4508.4508

Published: 2016

Journal Articles

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

Elizabeth H Phillips, Amy A Kirkwood, Anthony Lawrie, Simon Rule, Russell Patmore, MRCP FRCPath, Ruth Pettengell, Cathy H Burton, Kirit M Ardeshna, Silvia Montoto, MD, Shankaranarayana Paneesha, Paul Smith, Katharina Wanek, Laura Clifton-Hadley, PhD BSc, David C. Linch, MD MRCP, MB BCh, BA, Andrew McMillan, PhD

Blood (2016) 128 (22): 1855.

https://doi.org/10.1182/blood.V128.22.1855.1855

Published: 2016

Journal Articles

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

Blood (2016) 127 (12): 1531–1538.

https://doi.org/10.1182/blood-2015-11-679407

Published: 2016

Includes: Supplemental data

Journal Articles

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Dina Okasha, Amy A Kirkwood, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Emma Lawrie, Andrew McMillan, PhD, Tobias F. Menne, MD PhD FRCPath, Nick Morley, Clare Rowntree, Deborah Susan Richardson, MDFRCPath,FRCP,MA,MBBChir, Paul Smith, Adele K. Fielding, MB BS, PhD, David Marks, MD PhD

Blood (2015) 126 (23): 733.

https://doi.org/10.1182/blood.V126.23.733.733

Published: 2015

Journal Articles

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Blood (2015) 126 (23): 1516.

https://doi.org/10.1182/blood.V126.23.1516.1516

Published: 2015

NARROW

Translationally Relevant Oral Ruxolitinib Dosing Reduces Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis

Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial

RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy

R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of WaldenstrőM's Macroglobulinemia: A Randomised Phase II Study

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only